Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

NCT02467920 · Completed

Last updated 2026-05-28

This clinical trial compared two diabetes treatments—adding exenatide twice daily to basal insulin glargine versus switching to a premixed insulin aspart regimen—in adults with type 2 diabetes who were not well-controlled on metformin and premixed human insulin.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 349 people

Who can join Ages 18–70 · all sexes

Timeline Started 2015-08 · est. completion 2017-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02467920 ↗

Description as written by the study sponsor.

Efficacy and Safety of Basal Insulin Glargine Combination with Exenatide bid vs Switching Premix Human Insulin to Aspart30 in T2DM with Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open, Parallel trial.

Treatments tested

glargine + exenatide Drug

glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
aspart 30 Drug

aspart 30 ( subcutaneous injection, twice daily)

Main thing measured	the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin.
Sponsor	Huazhong University of Science and Technology
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02467920 ↗